greeksoup/ stock research
Stock research / United States / Funds / Defilade Capital Management, L.P.

Defilade Capital Management, L.P.

CIK 2088557 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Defilade Capital Management, L.P. reported 39 US-listed holdings worth $746.9 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Eli Lilly & Co. (6.3%), Pfizer Inc. (5.7%) and Veeva Systems Inc. (5.6%). Against the quarter before, it opened 20 positions, added to 8, trimmed 10 and sold out of 12.

Reported holdings$746.9M+4.9% on Q1 2026
Positions39+8 on Q1 2026
The largest ten46.5%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toTrimmed
LLY6.3%PFE5.7%VEEV5.6%BMRN5.2%PTCT4.7%BAX4.2%INSM4.0%ZBH3.7%PODD3.6%TMO3.5%ABT3.5%ASND3.4%SOLV3.3%MDT3.2%25 more40.2%

The 14 largest of its 39 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q4 2025: $737.7 million in 33 positions$738MQ4 25Q1 2026: $712.2 million in 31 positions$712MQ1 26Q2 2026: $746.9 million in 39 positions$747MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +3.1% over the 2 quarters to 30 June 2026, against +9.5% for the S&P 500.

Its reported holdingsThe S&P 500
95100105110Q4 25Q1 26Q2 26Its holdings +3.1%S&P 500 +9.5%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Opened 20Added 8Held 1Trimmed 10Sold out 12
Opened: 20Added: 8Held: 1Trimmed: 10Sold out: 12

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 20

  1. Veeva Systems Inc. VEEV$42.0 million
  2. Biomarin Pharmaceutical Inc. BMRN$39.0 million
  3. Baxter International Inc. BAX$31.1 million
  4. Insulet Corp. PODD$26.9 million
  5. Thermo Fisher Scientific Inc. TMO$26.0 million
  6. Abbott Laboratories ABT$25.9 million
  7. Ascendis Pharma A/s ASND$25.3 million
  8. Solventum Corp. SOLV$24.4 million

and 12 more in the table below

Added to 8

  1. Eli Lilly & Co. LLY+18,390 shares · +89%
  2. Insmed Inc. INSM+86,929 shares · +45%
  3. Pfizer Inc. PFE+307,614 shares · +21%
  4. PTC Therapeutics, Inc. PTCT+57,534 shares · +15%
  5. Oric Pharmaceuticals Inc. ORIC+204,762 shares · +24%
  6. Cogent Biosciences Inc. COGT+40,851 shares · +12%
  7. Evommune Inc. EVMN+114,556 shares · +17%
  8. Ocular Therapeutix Inc. OCUL+2,641 shares · +0%

Trimmed 10

  1. Revolution Medicines, Inc. RVMD-233,145 shares · -74%
  2. Denali Therapeutics Inc. DNLI-968,103 shares · -71%
  3. Zimmer Biomet Holdings, Inc. ZBH-261,735 shares · -45%
  4. ICU Medical Inc. ICUI-148,591 shares · -58%
  5. Globus Medical Inc. GMED-214,713 shares · -61%
  6. Pacs Group Inc. PACS-388,505 shares · -64%
  7. Lantheus Holdings, Inc. LNTH-116,739 shares · -47%
  8. Olema Pharmaceuticals Inc. OLMA-579,778 shares · -39%

and 2 more in the table below

Sold out of 12

  1. Henry Schein Inc. HSIC$46.0 million last quarter
  2. Becton Dickinson & Co. BDX$43.9 million last quarter
  3. Dexcom Inc. DXCM$33.8 million last quarter
  4. Intuitive Surgical Inc. ISRG$31.2 million last quarter
  5. Neurocrine Biosciences Inc. NBIX$27.7 million last quarter
  6. Integer Holdings Corp. ITGR$18.7 million last quarter
  7. Biogen Inc. BIIB$17.7 million last quarter
  8. Tandem Diabetes Care Inc. TNDM$14.6 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Eli Lilly & Co. LLY39.1K$46.9 million6.28%+18.4K
Pfizer Inc. PFE1.8M$42.7 million5.71%+307.6K
Veeva Systems Inc. VEEV236.7K$42.0 million5.62%new
Biomarin Pharmaceutical Inc. BMRN682.0K$39.0 million5.22%new
PTC Therapeutics, Inc. PTCT433.7K$35.4 million4.74%+57.5K
Baxter International Inc. BAX1.5M$31.1 million4.17%new
Insmed Inc. INSM281.8K$30.0 million4.02%+86.9K
Zimmer Biomet Holdings, Inc. ZBH317.4K$27.3 million3.66%-261.7K
Insulet Corp. PODD176.9K$26.9 million3.61%new
Thermo Fisher Scientific Inc. TMO51.9K$26.0 million3.49%new
Abbott Laboratories ABT285.8K$25.9 million3.47%new
Ascendis Pharma A/s ASND94.8K$25.3 million3.39%new
Solventum Corp. SOLV316.5K$24.4 million3.27%new
Medtronic plc MDT303.3K$23.7 million3.18%new
Elanco Animal Health Inc. ELAN864.1K$21.3 million2.85%-67.0K
Agios Pharmaceuticals Inc. AGIO546.8K$20.3 million2.72%new
Envista Holdings Corp. NVST726.1K$19.1 million2.56%new
Revolution Medicines, Inc. RVMD82.8K$15.5 million2.08%-233.1K
ICU Medical Inc. ICUI105.7K$15.5 million2.07%-148.6K
Cogent Biosciences Inc. COGT393.4K$15.2 million2.04%+40.9K
Lantheus Holdings, Inc. LNTH132.7K$14.7 million1.97%-116.7K
Ocular Therapeutix Inc. OCUL1.5M$14.6 million1.96%+2.6K
Eledon Pharmaceuticals Inc. ELDN3.5M$13.9 million1.86%-38.8K
Tyra Biosciences Inc. TYRA376.9K$12.0 million1.61%new
Olema Pharmaceuticals Inc. OLMA924.8K$11.6 million1.55%-579.8K
Oric Pharmaceuticals Inc. ORIC1.0M$11.3 million1.52%+204.8K
Larimar Therapeutics Inc. LRMR3.7M$11.2 million1.50%new
Globus Medical Inc. GMED139.6K$11.0 million1.48%-214.7K
Enovis Corp. ENOV531.9K$11.0 million1.47%new
Evommune Inc. EVMN793.1K$10.5 million1.41%+114.6K
Teleflex Inc. TFX80.1K$10.2 million1.36%new
Denali Therapeutics Inc. DNLI391.9K$10.1 million1.35%-968.1K
Glaukos Corp. GKOS66.5K$9.3 million1.24%new
Staar Surgical Co. STAA322.1K$9.2 million1.24%new
Pacs Group Inc. PACS215.7K$9.2 million1.23%-388.5K
Crinetics Pharmaceuticals in CRNX239.4K$9.0 million1.20%new
LivaNova plc LIVN107.4K$8.8 million1.18%new
Black Diamond Therapeutics I BDTX1.7M$3.1 million0.41%new
Mereo Biopharma Group PLC MREO7.6M$2.4 million0.32%no change
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 12 it sold out of are in the box above.